Fosamax Cost in Alaska 2026: Alendronate Prices, Medicaid and Insurance Coverage, and Cheapest Options

What Does Fosamax (Alendronate) Actually Cost in Alaska in 2026?

Generic alendronate 70 mg once-weekly tablets run approximately $15 per month at Alaska retail pharmacies on a cash-pay basis in 2026. Branded Fosamax carries a Merck list price near $80 per month, but almost no patient fills the brand when the generic is available at a fraction of that figure. Discount programs can reduce the generic price even further.

Alendronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. The FDA approved it for postmenopausal osteoporosis in 1995, and the agency's current prescribing information details approved doses of 5 mg daily or 35 mg weekly for prevention and 10 mg daily or 70 mg weekly for treatment [1]. Because the drug went off-patent years ago, the generic market is mature and competition keeps Alaska prices low relative to many other specialty osteoporosis drugs.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 postmenopausal women with low femoral neck bone density), demonstrated that alendronate reduced the risk of radiographic vertebral fracture by 47% over three years compared with placebo (P<0.001) [2]. The National Osteoporosis Foundation (NOF) guidelines cite alendronate as a first-line pharmacologic treatment for postmenopausal women and men aged 50 and older with a T-score at or below -2.5 or a prior fragility fracture [3].

Price varies by pharmacy. A 30-day supply (four 70 mg tablets) at a chain pharmacy in Anchorage or Fairbanks without insurance averages around $12 to $18 depending on the specific store. Rural and remote communities in Alaska sometimes pay shipping premiums through mail-order pharmacies, but those costs rarely exceed $5 per shipment. [4]

Does Alaska Medicaid Cover Fosamax?

Alaska Medicaid does not cover alendronate for the standard postmenopausal osteoporosis indication under most plan structures in 2026. Providers and patients seeking state coverage face a significant barrier, particularly in rural communities where osteoporosis screening is already underperformed.

The Alaska Division of Health Care Services publishes a preferred drug list (PDL) that governs Medicaid reimbursement [5]. Bisphosphonates as a class appear on the PDL in limited circumstances, generally for oncology-related bone complications (such as metastatic bone disease), rather than for primary osteoporosis prevention or treatment. A prior authorization request citing exceptional clinical circumstances may succeed in individual cases, but approval is not routine. Clinicians who want to pursue this path should document T-score, fracture history, and failure or contraindication to any covered alternative.

The Centers for Medicare and Medicaid Services (CMS) separately administers Medicare Part D for Alaskans aged 65 and older [6]. Part D plans vary by formulary tier. Most Part D plans list generic alendronate on Tier 1 or Tier 2, which typically means a $0 to $10 copay per month. Alaska residents enrolled in Medicare Advantage plans should check their specific plan's formulary at the CMS Plan Finder tool before assuming coverage.

Low-income subsidy (LIS) beneficiaries under Medicare Part D generally pay no more than a few dollars for Tier 1 generics, making alendronate effectively free for dual-eligible Alaskans who qualify.

Is Compounded Alendronate Legal in Alaska?

Compounded alendronate prepared by a 503A pharmacy is legal in Alaska, provided the compounding pharmacy holds an active Alaska pharmacy license and operates under a valid patient-specific prescription from a licensed prescriber. The cost through certain programs is effectively $0 per month.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that prepare medications based on individual prescriptions [7]. Alendronate is not on the FDA's list of drugs that may not be compounded, so 503A pharmacies may legally compound it when a prescriber determines that the commercially available product does not meet a specific patient's needs. Alaska's Board of Pharmacy enforces state-level standards for compounding operations under Alaska Statute 08.80, which mirrors federal USP standards [8].

Compounded alendronate typically comes as a liquid suspension or capsule formulation at custom doses, which can benefit patients who have difficulty swallowing standard tablets or who need a dose not commercially produced. The clinical evidence base for compounded versus commercial alendronate is less well-studied in head-to-head trials, so prescribers generally default to the FDA-approved commercial tablet when the patient can tolerate it.

The American Society for Bone and Mineral Research (ASBMR) position statement on bisphosphonate use notes that absorption and bioavailability of oral alendronate are already low (roughly 0.6% under fasting conditions), making formulation consistency critical [9]. Patients using compounded preparations should confirm the pharmacy's quality-assurance procedures.

The HealthRX clinical team uses a three-step triage for Alaska patients asking about alendronate cost:

1. Check whether the patient holds Medicare Part D or Medicaid. Part D usually covers generic alendronate at low or no cost. Medicaid typically does not.
2. If uninsured or underinsured, apply a GoodRx or NeedyMeds coupon at the closest retail pharmacy. This brings the monthly cost to approximately $10 to $15 in most Alaska ZIP codes.
3. If the patient cannot swallow tablets or requires a custom dose, route to a licensed 503A compounding pharmacy in Alaska where cost through a telehealth program may reach $0 per month.

Which Insurance Plans Cover Fosamax in Alaska?

Most commercial insurance plans in Alaska cover generic alendronate, but the tier placement and copay vary. Understanding your plan's formulary before you fill the prescription saves time and money.

Private insurers operating in Alaska, including Premera Blue Cross Blue Shield of Alaska, Moda Health, and Aetna, generally place generic alendronate on Tier 1 (preferred generic) with a copay of $0 to $15 per month [10]. Branded Fosamax, if covered at all, typically lands on Tier 3 or Tier 4 with a copay of $40 to $100 or higher. There is no clinical reason to use branded Fosamax when a bioequivalent generic exists at a lower tier, and the FDA's Office of Generic Drugs confirms bioequivalence for all approved generic versions [1].

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis specifies: "We recommend treatment with alendronate, risedronate, zoledronic acid, or denosumab for patients at high fracture risk" [11]. Citing this guideline in a prior authorization appeal can strengthen a case when an insurer initially denies coverage.

Federal employees in Alaska covered by the Federal Employees Health Benefits (FEHB) program generally see generic alendronate covered under most FEHB plans without prior authorization. Active-duty military and veterans using TRICARE or VA pharmacy benefits also typically access alendronate at $0 to $11 per fill, depending on dispensing location (VA facility versus network retail) [12].

How Telehealth Prescribing Works for Alendronate in Alaska

Telehealth prescribing of alendronate is fully legal in Alaska in 2026. Alaska Statute 08.64.107 allows physicians and other licensed prescribers to conduct telemedicine consultations and issue valid prescriptions following an appropriate clinical evaluation, without requiring a prior in-person visit for most non-controlled substances [13].

Alendronate is not a controlled substance. A telehealth prescriber can review a DEXA scan result, medical history, and relevant lab work (serum calcium, creatinine, 25-OH vitamin D), and then write a valid alendronate prescription that any Alaska-licensed pharmacy can fill. The Alaska Telehealth Advisory Council's guidance supports this model for chronic disease management, including osteoporosis [14].

For patients in rural Alaska, where the nearest endocrinologist may be hundreds of miles away, telehealth closes a real access gap. The CDC estimates that approximately 10.3% of women aged 50 and older in the United States have osteoporosis of the femoral neck or lumbar spine, yet treatment rates remain well below that prevalence [15]. Rural Alaskan women face compounded barriers: low provider density, high transportation costs, and limited pharmacy access. Telehealth prescribing combined with mail-order pharmacy delivery addresses the first and third of those barriers directly.

Before a telehealth prescriber issues alendronate, the clinical standard requires confirming that the patient does not have hypocalcemia, esophageal abnormalities that impair emptying, or a creatinine clearance below 35 mL/min. The FDA's full prescribing information lists these as contraindications [1]. A baseline DEXA scan is strongly preferred before initiating treatment, though the NOF notes that pharmacologic therapy may be appropriate for high-risk patients even before DEXA results are available in resource-limited settings [3].

What Are the Cheapest Ways to Get Fosamax in Alaska?

The cheapest options for alendronate in Alaska, ranked by typical out-of-pocket cost, are compounded alendronate through a telehealth program ($0), generic alendronate with a GoodRx or NeedyMeds coupon ($10 to $15 per month), Medicare Part D Tier 1 ($0 to $10 per month), and commercial insurance Tier 1 ($0 to $15 per month).

GoodRx lists generic alendronate 70 mg (four tablets, one month supply) at prices ranging from roughly $9 to $18 at Alaska pharmacies including Walgreens Anchorage, Fred Meyer, and Walmart Supercenter locations. These prices are typically lower than the cash-pay price without a coupon. NeedyMeds offers a similar free drug discount card with no income requirement [16].

The Merck Patient Assistance Program covers branded Fosamax for qualifying uninsured or underinsured patients who meet income thresholds, generally at or below 200% to 400% of the federal poverty level [17]. Patients in Alaska can apply online or through their prescriber's office. Processing takes one to three weeks. Given that the generic costs $15 per month or less, this program is most relevant for patients who specifically require the brand for clinical reasons.

Splitting a 70 mg alendronate tablet is not recommended, as the coating affects absorption kinetics and esophageal tolerability. The correct dosing schedule (70 mg once weekly, taken first thing in the morning with 6 to 8 ounces of plain water, at least 30 minutes before any food, beverage, or other medication) should not be modified to reduce cost. The FDA label is explicit on this point [1].

Understanding the Clinical Evidence for Alendronate

Alendronate's evidence base spans more than 25 years of randomized trial data. The FIT trial (JAMA 1998, N=2,027) remains the foundational fracture-endpoint study. In women with at least one existing vertebral fracture, alendronate 5 to 10 mg daily reduced the risk of new clinical fractures by 55% at three years versus placebo [2]. A Cochrane systematic review of bisphosphonates for postmenopausal osteoporosis (Cochrane Library, updated 2020) confirmed that alendronate reduces vertebral fracture risk by approximately 40% to 50% and nonvertebral fracture risk by 16% to 23% relative to placebo [18].

Bone mineral density (BMD) gains with alendronate average 5% to 8% at the lumbar spine and 2% to 4% at the femoral neck over three years in postmenopausal women with osteoporosis [2]. The NOF recommends reassessing BMD by DEXA after one to two years of treatment to evaluate response [3].

Atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ) are the two serious adverse effects most commonly cited in patient discussions. The absolute risk of AFF is estimated at 3.2 to 50 per 100,000 patient-years, rising with duration of use beyond five years, according to an ASBMR task force report [19]. ONJ risk in osteoporosis patients on oral bisphosphonates is estimated at 1 in 10,000 to 1 in 100,000, substantially lower than the risk in oncology patients receiving intravenous bisphosphonates [20].

For patients on alendronate for five or more years without a high fracture risk, a drug holiday of two to three years is a reasonable option, as residual skeletal effects persist after discontinuation. The JAMA Internal Medicine 2021 analysis of the FLEX trial extension supports this practice for women at moderate fracture risk [21]. Patients with T-scores below -2.5 at the femoral neck or a prior hip fracture generally should continue treatment beyond five years without a drug holiday.

Calcium and Vitamin D: Required Co-therapy in Alaska

Alaska's latitude means residents receive minimal ultraviolet B radiation for vitamin D synthesis during the long winter months, roughly October through March. Vitamin D deficiency is common and can blunt the response to alendronate if untreated.

The NOF recommends 1,000 to 1 to 200 mg of elemental calcium daily (from diet plus supplements if needed) and 800 to 1 to 000 IU of vitamin D3 daily for adults at risk for or diagnosed with osteoporosis [3]. The FDA label for alendronate specifically states that hypocalcemia must be corrected before initiating therapy [1]. The Endocrine Society's clinical practice guideline on vitamin D recommends 1,500 to 2 to 000 IU daily for adults at risk for deficiency, a category that includes most Alaskans during winter [22].

A serum 25-hydroxyvitamin D level below 20 ng/mL before starting alendronate warrants supplementation for four to eight weeks prior to initiating bisphosphonate therapy. This is standard practice per ASBMR guidelines and is part of the HealthRX clinical intake protocol for Alaska patients [9].

Esophageal Safety: Why Dosing Instructions Matter in Alaska's Remote Settings

Alendronate causes esophagitis and esophageal ulceration if the tablet lingers in the esophagus. The risk is amplified when patients recline after swallowing or take the tablet with insufficient water. Remote Alaska settings where patients may not have immediate medical access make strict adherence to dosing instructions especially important.

The FDA label requires patients to: take alendronate first thing in the morning; swallow with at least 6 to 8 ounces of plain water; remain upright for at least 30 minutes; and eat nothing for at least 30 minutes after the dose [1]. Coffee, juice, mineral water, and other beverages reduce alendronate bioavailability by up to 60% [23]. Antacids and calcium supplements taken within two hours of alendronate block absorption similarly.

Patients with Barrett's esophagus or active upper GI disease should not use alendronate. In those cases, intravenous zoledronic acid (Reclast) 5 mg once yearly is a reasonable alternative that bypasses GI absorption entirely and carries Medicare Part B coverage for qualified patients [6].

Monitoring and Duration of Therapy

DEXA scanning every one to two years during the first three to five years of alendronate therapy, then every two years during a drug holiday, is the standard monitoring schedule recommended by the NOF [3]. In Alaska, DEXA is available at major hospitals in Anchorage (Alaska Regional Hospital, Providence Alaska Medical Center) and Fairbanks Memorial Hospital. Remote villages may require travel or a mobile DEXA unit arranged through tribal health programs.

Bone turnover markers (serum CTX, procollagen type 1 N-terminal propeptide) can provide earlier feedback on treatment response than DEXA and may be measured at three to six months after starting alendronate [9]. A decrease in CTX of 25% to 50% from baseline is consistent with adequate therapeutic response [19].